High multiple mutations of *Plasmodium falciparum*-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria

Hong Quan1,2, Uche Igbasi3, Wellington Oyibo4, Sunday Omilabu5, Shen-Bo Chen1,2, Hai-Mo Shen1,2, Chukwuma Okolie6, Jun-Hu Chen1,2† and Xiao-Nong Zhou1,2

Abstract

**Background:** *Plasmodium falciparum*-resistance to sulphadoxine-pyrimethamine (SP) has been largely reported among pregnant women. However, the profile of resistance markers to SP dihydrofolate reductase (*dhfr*) and dihydropteroate synthase (*dhps*) in the general population are varied and not frequently monitored. Currently, SP is used as partner drug for artemisinin combination therapy (SP-artesunate) in some sub-Saharan African countries or as a prophylactic drug in intermittent preventive treatment of malaria during pregnancy and infants and in seasonal malaria chemoprevention (SMC). Profiling of *P. falciparum*-resistant genotypes to SP is dynamic and critical in providing data that would be useful for malaria control programmes. This study assessed the profile of *dhfr* and *dhps* genes genotypes among individuals with malaria in Lagos, Nigeria.

**Methods:** Molecular markers of SP resistance were identified by nested PCR and sequenced among malaria positive dried blood spots (DBS) that were collected from individuals attending health facilities from January 2013 to February 2014 and during community surveys from October 2010 to September 2011 across different Local Government Areas of Lagos State, Nigeria.

(Continued on next page)
Background
The efficacy of antimalarial medicines is critical to the implementation of effective malaria case management where patients confirmed to have malaria parasites are treated promptly. Consequently, failing antimalarial medicines due to parasite resistance will greatly affect the attainment of the case management goal. Resistance to antimalarial drugs has been described for *Plasmodium falciparum,* the predominant *Plasmodium* species in Africa [1]. Over a decade, sulphadoxine-pyrimethamine (SP) was the second-line treatment medicine while chloroquine (CQ) served as the first-line antimalarial medicine for the treatment of uncomplicated *P. falciparum* malaria [2]. *P. falciparum,* unfortunately developed resistance to both widely used medicines and are not currently recommended for the treatment of malaria as monotherapies in the general population. The malaria parasite’s resistance to SP is due to point mutations in target enzymes, dihydrofolate reductase (*dhfr*) and dihydropteroate synthase (*dhps*) [3]. Resistance to SP and CQ were reported at different times in the history of anti-malarial medicine resistance [4, 5].

Currently, SP is used as a partner drug for antimalarial drug resistance (ACT, such as SP-artsunate), seasonal malaria chemoprevention (SMC) in areas where it is recommended, intermittent preventive treatment of malaria in infants and children (IPTi & c) in some sub-Saharan African countries, and as intermittent preventive treatment of malaria in pregnancy (IPTp) [6]. The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment of malaria in pregnancy (MiP) with SP (IPTp-SP) and other interventions including SMC across Africa. In West Africa, SP resistant genes of *P. falciparum* have been reported, and IPTp-SP remains the interventional strategy for the prevention of malaria in pregnancy [7]. Studies in Nigeria have reported varying mutant combinations with over 50.0–96.9% prevalence of SP-resistant mutations in the last decade [8–10].

SP acts primarily on the schizonts during the hepatic and erythrocytic phases of the plasmodia life cycle [11], by inhibiting enzymes necessary for parasite folate biosynthesis. Pyrimethamine acts by inhibiting *dhfr* in the parasite [12], thus preventing the biosynthesis of purines and pyrimidines, while sulphadoxine binds the enzyme *dhps* [13], inhibiting the use of para-aminobenzoic acid during the synthesis of dihydropteroic acid. When combined the two key stages in DNA synthesis in the plasmodia are prevented consequently, cell division and reproduction are halted. As these two drugs target the same pathway and act synergistically, they are usually given in combination as SP but referred to as monotherapy [14].

Mutations in the *dhfr* and *dhps* genes of *P. falciparum* parasites have been associated with decreased parasite sensitivity to the anti-folate drugs. In both genes, each successive mutation has been shown to incrementally increase the parasite’s tolerance to the drug in vitro [14]. A change from wild type serine 108 to asparagine108 (S108N) in *dhfr* is sufficient to cause low level pyrimethamine resistance both in vitro and in vivo [15]; this represents the initial and critical mutation for pyrimethamine. Additional mutation(s) at positions 50: C50R, 51: N51I, 59: C59R and I164L synergistically increase the levels of resistance [16, 17]. Furthermore, mutation from alanine to glycine at codon 437 (A437G) for *dhps* represents the critical mutation for sulphadoxine resistance and additional mutation(s) at positions 436 (S436A/F), 540 (K540E), 581 (A581G), and 613 (A613S/T) have been associated with decreased parasite sensitivity to the sulpha drugs including sulphadoxine and dapson [13, 18, 19]. Mutations at codons 437 and 540 of *dhps* play the most significant role in sulphadoxine resistance among African parasites. In East and South Africa, mutations at the 437 and 540

Results: A total of 242 and 167 samples were sequenced for *dhfr* and *dhps,* respectively. Sequence analysis of *dhfr* showed that 95.5% (231/242), 96.3% (233/242) and 96.7% (234/242) of the samples had NSI, C59R and S108N mutant alleles, respectively. The prevalence of *dhps* mutation at codons A437G, A613S, S436A, A581G, I431V and K540E were 95.8% (160/167), 41.9% (70/167), 41.3% (69/167), 31.1% (52/167), 25.1% (42/167), and 1.2% (2/167) respectively. The prevalence of triple mutations (*CIRNI*) in *dhfr* was 93.8% and 44.3% for the single *dhps* haplotype mutation (SGKAA). Partial SP-resistance due to quadruple *dhfr-dhps* haplotype mutations (*CIRNI-VAGKKS*) and octuple haplotype mutations (*CIRNI-VAGKGS*) with rate of 42.6% and 22.0%, respectively has been reported.

Conclusions: There was increased prevalence in *dhfr* triple haplotype mutations when compared with previous reports in the same environment but aligned with high prevalence in other locations in Nigeria and other countries in Africa. Also, high prevalence of *dhfr* and *dhps* mutant alleles occurred in the study areas in Lagos, Nigeria five to eight years after the introduction of artemisinin combination therapy underscores the need for continuous monitoring.

Keywords: *Plasmodium falciparum,* Antimalarial drug resistance, Sulphadoxine–pyrimethamine, Dihydrofolate reductase, Dihydropteroate synthase
codons are found together while in West and Central Africa the 437 is found on its own [20]. However, mutation at codon 431 (I431V) has been scarcely reported. It was first reported among imported malaria infections that originated from Nigeria in 2009 [21] and pregnant women from Cameroon in 2015 [22, 23], though its effect on parasite susceptibility to SP is yet to be fully described [10].

It has been demonstrated that the accumulation of single nucleotide polymorphisms (SNPs) in \( dhfr \) and \( dhps \) genes increases the levels of SP resistance in vivo [23]. In West and Central Africa, a triple mutant genotype of \( dhfr \) (N51I, C59R and S108N) combined with the A437G mutation in the \( dhps \) gene has been related to SP treatment failure [24]. Another significant predictor of SP treatment failure is the quintuple mutant genotype, which includes the \( dhfr \) triple mutations (N51I, C59R and S108N) combined with the \( dhps \) double mutations (A437G + K540E) [25–27].

In Nigeria, high prevalence of triple mutant genotype of \( dhfr \) (N51I, C59R and S108N) combined with A437G mutation in the \( dhps \) gene have been reported [10], but reports of quintuple \( dhfr/dhps \) mutation comprising of (N51I, C59R and S108N) plus (A437G + K540E) is scarce [10].

SP-resistant parasites could be classified as “partially resistant”, “fully resistant” and “super resistant” [28]. The parasites are classified based on the combination of mutations they carry in the two genes (\( dhfr \) and \( dhps \)). The quadruple combination of triple mutation, \( dhfr \) N51I, C59R, S108N and \( dhps \) A437G, confers partial resistance; the quintuple combination of triple mutations, \( dhfr \) N51I, C59R, S108N and double mutation, \( dhps \) A437G, K540E, confers full resistance; and the sextuple combination of triple mutation, \( dhfr \) N51I, C59R, S108N and triple mutation, \( dhps \) A437G, K540E, A581G, confers super resistance [28]. These haplotype mutations affect the outcome of IPTp and IPTi [28].

Molecular genotyping and characterization of single nucleotide polymorphisms (SNPs) used in drug resistance monitoring could provide red flags of threats to continued use of SP in strategies planned by countries. This study provides data for trend profiling of molecular markers of resistance to antifolate drugs from isolates of \( Plasmodium falciparum \) from stored patients’ DBS obtained between 2010 and 2014 in Lagos, South-West, Nigeria.

Methods

Study area

The study was conducted in Lagos State, Nigeria. Lagos State is an African megacity located in south-western Nigeria on the west coast of Africa, within latitudes 6023’N and 6041’N and longitudes 2042’E and 3042’E (Fig. 1) and has an estimated population of over 10 million inhabitants, which is more than 10% of the total population of Nigeria. The state is a low-lying coastal State and Nigeria’s centre of commerce, accounting for more than 70% of the nation’s industrial and commercial establishments. Lagos is a centre of commerce with very diverse and fast-growing population, with high migration to its cities from all parts of Nigeria as well as neighbouring and foreign countries.

There are 20 Local Government Areas (LGAs) from where 50 Local Council Development Areas (LCDAs) were carved for ease of administration. The land surface generally slopes gently downwards from north to south and is naturally made up of depositional landforms which include: wetlands, barrier islands, beaches, low-lying tidal flats and estuaries [29]. Furthermore, Lagos is hypo-endemic for malaria during the dry season with moderate and stable transmission but peaks during the wet season due to increase in the population of mosquitoes [30].

Study population and sites

The samples used for this study were obtained from children and adult patients that presented with fever/symptoms of malaria in the last 48 h in a cross-sectional case management study in health facilities (January 2013 to February 2014) and from asymptomatic persons in community surveys (October 2010 to September 2011). The health facilities were: Ejede General Hospital (H1), Imota Primary Health Centre (H2), Bayioku Primary Health Centre (H3), Agura Primary Health Centre (H4). These four health centres are situated in Ikorodu LGA. St. Kizito Primary Health Centre, Lekki in Ibeju Lekki LGA (H5), St Mathew Primary Health Centre (Catholic), Ajegunle, Amukoko in Ajeromi Ifelodu LGA (H6), and in Shomolu General Hospital, Shomolu LGA (H7) (Fig. 1). The asymptomatic study was conducted in persons aged 2 months and above in communities that were randomly and purposively selected based on malaria endemicity data, and enrolment was done using multi-stage and stratified sampling in households. The communities were: 1) Ipakodo in Ikorodu LGA, 2) Agbowa, 3) Ajagunmagbe, 4) Noforija in Epe LGA, 5) Lekki in Ibeju Lekki LGA, 6) Maidian Community, 7) Owode/Ajegunle, 8) Owode/Elede in Kosofe LGA, 9) Badagry town, 10) Apa in Badagry LGA, 11) Sura in Lagos Island LGA, 12) Ijora, 13) Abete, 14) Akere, 15) Alayabiagba in Apapa LGA, 16) Otto in Lagos Mainland LGA, 17) Monkey Village, 18) Ijegun in Amuwo Odofin LGA, 19) Aburo in Alimosho LGA, 20) Tedi-Muwo in Ojo LGA (Fig. 1).

Preparation of dry blood spots

Dry blood spots were prepared from approximately 3–4 drops of blood collected from the study participants.
(both in the health facility and community) on filter paper (Whatman® filter paper #3, Whatman International Ltd., Maidstone, England). Thick and thin malaria blood films (MBFs) for malaria microscopy were also prepared for each person. The prepared blood spots were air-dried and kept in a zip-lock bag with desiccant and stored at 2–8 °C for molecular analysis.

Malaria microscopy
Malaria microscopy on the prepared MBFs was done using standard protocol and read by independent microscopist to identify malaria positive smears [31]. The results of the malaria microscopy were used in the selection of DBS for the molecular profiling of *P. falciparum*-resistant genes and haplotypes to SP.

DNA extraction and PCR amplification
A subset of 404 dB from the samples positive for *P. falciparum* mono infection was used for this study. Three milliliter diameter punches were made from the DBS with single-hole paper puncher. Sterilization of the puncher was done after every punch of each patient’s DBS with 70% soaked alcohol swab. The punched blood spot was placed into a 1.5 ml micro centrifuge tube. The genomic DNA from the DBSs was extracted using the QIAamp® DNA Mini kit (Qiagen, Germany) according to the manufacturer’s instructions. The DNA extracted was finally eluted using 50 μl elution buffer and kept at −20 °C.

Nested PCR was used to amplify the extracted DNA. The primary and secondary amplification were done in a 25 μl reaction mixture that comprised of 2 μl of template genomic DNA, 1 μl of primer F, 1 μl of primer R, 12.5 μl of Taq 2x DNA master mix (Sangon Bio Inc., Shanghai, China) and 8.5 μl of double distilled water (ddH2O) using specific primers and cycling condition for the different genes.

The *dhfr* genes were amplified using the primer as previously described [32]; Forward: 5′-TCCTTCTCTTTGATGGAACAAG-3′, Reverse: 5′-AGTATATACACTCGCTAACAAG-3′, and cycling conditions; initial denaturation for 5 min at 94 °C; 35 cycles at 95 °C for 30 s, 50 °C for 30 s and 68 °C for 1 min, final extension at 68 °C for 5 min. 2 μl of the PCR product was used in the second round amplification with specified primers; Forward: 5′-TTATGATGGAACAGATTCTGC-3′, Reverse:
5′-ACTCAATTTTCATTATTTTCTGG-3′, and cycling conditions; 5 min at 94°C, 30 cycles at 94°C for 30 s, 52°C for 30 s and 68°C for 1 min, final extension at 68°C for 5 min.

The dhps genes were amplified using the primer as previously described [33]; Forward: 5′-AACCTAAACG TGCTGCGTCTCAG-3′, Reverse: 5′-AATTGCTGTA TTTGGCCACAA-3′, and cycling conditions; initial denaturation for 5 min at 95°C, 35 cycles at 95°C for 30 s, 50°C for 30 s and 68°C for 1 min, final extension at 68°C for 5 min. 2 μl of the PCR product was used in the second round amplification with specified primers; Forward: 5′-ATGATAATGAAAGGTGCTAG-3′, Reverse: 5′-TCATTTCATTTCCATCATGT-3′, and cycling conditions; 5 min at 94°C, 30 cycles at 95°C for 30 s, 52°C for 30 s and 68°C for 1 min, final extension at 68°C for 5 min. The expected PCR product is 647 bp.

Positive controls were obtained from BEI Resources, USA (parasite Genomic DNA IPC 3663/3D7 strains and Dd2_R539T/Dd2 strains) and were used as references for susceptible and resistant genotypes, respectively. Nuclease-free water was used as a negative control.

The nested PCR products for dhfr and dhps were loaded on a 1% agarose gel containing 0.5 μg/ml ethidium bromide. Amplified bands of DNA were visualized under ultraviolet illumination and positive samples were selected for sequencing. The amplicon for the different genes were sequenced on an Applied Biosystem 3130 × 1 Genetic analyzer (Applied Biosystems, Foster City, CA, USA). Sequence alignment was done with DNAStar 7.1 software and analyzed using the reference: Plasmodium falciparum 3D7 dhps sensitive strain (NCBI reference Sequence: XM_000349382.1) and dhfr sensitive strain (NCBI Reference Sequence: XM_000351443.1), respectively.

**Ethical considerations**

The participants (in the health facility and community) gave written consent to participate and for their blood samples to be used for further malaria testing. Participants who presented at the screening for malaria that did not agree to participate were also attended to and standard care provided appropriately. All samples had only study identification numbers that could not be linked with personal details of the participants. The study protocol was approved by the Research Grants and Experimentation Ethics Committee, College of Medicine, University of Lagos, Nigeria and the Ethics Committee of the National Institute of Parasitic Diseases (NIPD), China.

**Results**

**Demographic characteristics**

Point mutations in dhps and dhfr were evaluated in 242 and 167 out of a cohort of 338 malaria-positive DBS obtained from symptomatic and asymptomatic individuals respectively from the study areas in Lagos, South – West, Nigeria between 2010 and 2014. The age of the participants were two months and above (range: 2 months–65 years; mean ± SD, 16.8 ± 14.1 years) (Table 1). The asexual parasitaemia of the study individuals ranged from 63 to 202 010 parasites/μl of blood (geometric mean parasite density of 7615 parasites/μl of blood).

**Prevalence of individual point mutations in dhfr and dhps**

The sequence analyses of dhfr at each codon showed that the 51I mutations appeared in 95.5% of the P. falciparum isolates. The prevalence of 59R and 108 N mutations was 96.3% and 96.7% respectively. However, the prevalence of P. falciparum isolates with wild dhfr was low and ranged from 3.3% (108 N) to 4.5% (51I) (Table 2).

Furthermore, the sequence analyses of dhps showed that the most prevalent mutation of the cohort of individuals examined was 437G (95.8%). Other mutations were: A613S (41.9%), S436A (41.3%), A581G (34.1%), I431V (25.1%) and K540E (1.2%) (Table 2). The genetic data from this study is deposited at the National Center for Biotechnology Information (NCBI). Accession numbers- BankIt2291211: MN985306–MN985306 (167 sequences) and BankIt2298803: MT140637–MT140882 (241 Sequences).

The frequency of dhfr and dhps mutations in the health facilities and communities occurred in varied proportions (Tables 3, 4, 5, 6). The health facility situated in Ijede, Ikorodu LGA had the highest number of samples and as well as the highest frequency of dhfr gene mutation at codons 51I, 59R and 108 N (Table 3) and dhps gene mutation at codons 431V, 436A, 437G, 581G and 613S (Table 4). Analysis of dhfr gene mutation among P. falciparum isolates from asymptomatic individuals from different communities showed that Lekki located in

**Table 1** Demographic characteristics of the cohort of individuals with positive dry blood spots that were used in the study in Lagos, Nigeria

| Description                                | n = 338 |
|--------------------------------------------|---------|
| Sex, n (%)                                 |         |
| Male                                       | 152 (45.0) |
| Female                                     | 186 (55.0) |
| Age category, n (%)                        |         |
| ≤ 5 years                                  | 68 (20.1) |
| 6–10 years                                 | 116 (34.3) |
| > 10 years                                 | 154 (45.6) |
| Parasite density (parasites/μl of blood)   |         |
| Range                                      | 63–202 010 |
| Geometric mean                             | 7615    |
Ibeju-Lekki LGA had the highest frequency of mutations at codons 51I, 59R and 108 N (Table 5) and dhps mutations at codons 431, 436, 437, 540, 581 and 613 (Table 6). Generally, there was no considerable difference in the occurrence of dhfr and dhps mutation across the sites in Lagos State.

Prevalence of dhfr and dhps haplotypes
Seven and seventeen distinct haplotypes occurred in dhfr and dhps, respectively in the cohorts of individuals in the study areas in Lagos (Table 7).

Dhfr haplotypes
Triple mutations in the dhfr haplotype (CIRNI) was the most prevalent (93.8%, 227/242) while 3.3% (8/242) of the isolates were wild type haplotype (CNCSI). The prevalence of double mutations in CICNI and CNRNI was 0.4% (1/242) and 1.2% (3/242) respectively while 1.2% of the samples had quadruple mutations at positions: 83R, 122 K and 160E together with the triple CIRNI mutations (Table 7).

Dhps haplotypes
Mutations in the dhps haplotype occurred in different proportions: single mutation in SGKAA was 44.3% (74/167). Quintuple mutations in VAGKGS (19.8%, 33/167) was the most prevalent of the multiple mutations compared to the triple, double and quadruple mutations that were recorded (Table 7).

Dhfr and dhps allele combinations
A total of 19 haplotypes were seen in the dhfr and dhps combinations (Table 8). Quadruple mutations occurred in the combined dhfr (triple mutations) + dhps (single mutation) haplotype (CIRNI + SGKAA) and was the most prevalent (42.6%, 60/141). This was followed by octuple mutations in CIRNI + VAGKGS (22.0%, 31/141). Sextuple mutations (CIRNI + AGKAS) and quintuple mutations (CIRNI + AGKAA) among the isolates were 9.9% and 5.0% respectively. Mutations in the haplotypes of the other combined genotypes were generally low (Table 8).

Discussion
P. falciparum drug resistance remains a challenge to effective malaria case management and prevention. This has made continuous monitoring of molecular markers of antimalarial drug resistance imperative in malaria-endemic countries to track trends and distribution of relevant resistant genes and haplotypes to ensure that threats to existing artemisinin combination therapies and drug-dependent interventions are identified and addressed promptly. Information on these threats will also further guide National Malaria Control Programmes to adopt the most suitable interventions using the appropriate drug combinations. Our study showed high frequencies of P. falciparum isolates with mutant dhfr and dhps in circulation in Lagos, Nigeria.

The dhfr triple haplotype mutation (CIRNI) was highly prevalent at all study sites in our study, which was

| LGA/ Health facility | Location of the health facilities | No. of samples sequenced for dhfr n (%) | dhfr mutation n (%) |  |
|----------------------|-----------------------------------|----------------------------------------|----------------------|---|
|                      |                                    |                                        | Wild     | NS1I | CS9R | S108N |
| Ilorun               | Ijede [H1]                         | 72 (34.0)                              | 3 (1.4)  | 69 (32.5) | 69 (32.5) | 69 (32.5) |
|                      | Imota [H2]                         | 27 (12.7)                              | 1 (0.5)  | 26 (12.3) | 26 (12.3) | 26 (12.3) |
|                      | Bayioku [H3]                       | 7 (3.3)                                | 0        | 7 (3.3)  | 7 (3.3)  | 7 (3.3)  |
|                      | Agura [H4]                         | 52 (24.5)                              | 3 (1.4)  | 49 (23.1) | 48 (22.6) | 49 (23.1) |
| Ajeromi - Ifelodun   | Amukoko [H6]                       | 35 (16.5)                              | 0        | 35 (16.5) | 33 (15.6) | 35 (16.5) |
| Shomolu             | Shomolu [H7]                       | 19 (9.0)                               | 0        | 19 (9.0)  | 19 (9.0)  | 19 (9.0)  |
| **Total**           |                                    | 212 (100)                              | 7 (3.3)  | 205 (96.7) | 202 (95.3) | 205 (96.7) |

LGA Local Government Area.
comparable with some other reported studies among pregnant women in Nigeria and in Sub Saharan Africa [9, 10, 34]. These reported studies indicating the authors, the mutation prevalence and the time of sample collection in Nigeria included: Agomo et al., 66.7% in Lagos in 2008/2009 [8], Iwalokun et al., 50.0% (Lagos) (2011) [9], and Oguike et al., 100.0% (Ibadan) (2003), 81.3% (Maiduguri) (2010), 90.2% (Enugu) (2010) and 98.7% in Benin city (2014/2015) [10]; and in Guinea, Jiang et al., 86.8% (Bioko Island) (2013/2014) [34]. There was an increase in dhfr triple haplotype mutations in Lagos within about 2 years. This mutation is associated with high-level resistance to pyrimethamine [35–37] and increased risk of SP resistance if it occurred concurrently with dhps mutations [26, 27, 36, 37]. Mutations such as 16 V+164 L in dhfr that are associated with high resistance to cycloguani, the active form of proguanil [37, 38] were not observed in our study in Lagos, Nigeria.

Mutations in dhps haplotypes at 437 occurred in 95.8%, 31.1% and 1.2% at codons 581 and 540 respectively in the samples analyzed. Amino acid changes at position 437 (A437G) represented the critical mutation for sulphadoxine resistance. Additional mutation(s) at positions 436 (S436A/F), 540 (K540E), 581 (A581G), and 613 (A613S/T) are associated with decreased parasite sensitivity to the sulpha drugs including sulphadoxine and dapsone [13, 18, 19]. Two (1.2%) dhps double haplotype mutation consisting of A437G and K540E were seen and have been consistently associated with in vivo clinical failure independently [26, 38]. Similarly, 581G dhps haplotype mutation has also been shown to be associated with important modulatory role in resistance [39]. The World Health Organization (WHO) recommends that when the frequency of this mutation is above 10.0%, IPTp with SP may not be able to protect pregnant women from delivering infants with low birth weight [40]. The 540E and 581G haplotype mutations have also

Table 4 Distribution of dhps mutations at the health facilities in Lagos, Nigeria

| LGA/Health facility | Location of health facilities | No. of samples sequenced for dhps n (%) | dhps mutation n (%) |
|---------------------|------------------------------|----------------------------------------|---------------------|
|                     |                              |                                        | A431V | A436S | A437G | KS40E | AS81G | A613S |
| Ikorodu             | Ijede [H1]                   | 50 (34.0)                              | 12 (8.2) | 28 (19.0) | 45 (30.6) | 0     | 14 (9.5) | 20 (13.6) |
|                     | Imota [H2]                   | 17 (11.6)                              | 5 (3.4)  | 9 (6.1)   | 16 (10.9) | 0     | 5 (3.4)  | 8 (5.4)   |
|                     | Bayioku [H3]                 | 5 (3.4)                                | 0       | 4 (2.7)   | 5 (3.4)   | 0     | 1 (0.7)  | 1 (0.7)   |
|                     | Agura [H4]                   | 26 (17.7)                              | 5 (3.4)  | 16 (10.9) | 24 (16.3) | 0     | 7 (4.8)  | 13 (8.8)  |
| Ajeromi-Ifeludun     | Amukoko [H6]                 | 31 (21.1)                              | 9 (6.1)  | 15 (10.2) | 28 (19.0) | 0     | 11 (7.5) | 15 (10.2) |
| Shomolu             | Shomolu [H7]                 | 18 (12.2)                              | 2 (1.4)  | 14 (9.5)  | 18 (12.2) | 2 (1.4) | 4 (2.7)  | 5 (3.4)   |
| Total               |                              | 147 (100)                              | 33 (22.4) | 83 (56.5) | 136 (92.5) | 2 (1.4) | 42 (28.6) | 62 (42.2) |

LGA Local Government Area.

Table 5 Distribution of dhfr mutations at the community locations in Lagos, Nigeria

| LGA/Community | Name of community | No. of samples sequenced for dhfr n (%) | dhfr mutation n (%) |
|---------------|-------------------|----------------------------------------|---------------------|
|               |                   |                                        | Wild | N51I | C59R | S108N |
| Ikorodu       | Ipakodo [1]       | 2 (6.7)                                | 0    | 2 (6.7) | 2 (6.7) | 2 (6.7) |
| Epe           | Agbowa [2]        | 5 (16.7)                               | 0    | 5 (16.7) | 5 (16.7) | 5 (16.7) |
|               | Noforija [4]      | 1 (3.3)                                | 0    | 1 (3.3)  | 1 (3.3)  | 1 (3.3)  |
| Ibeju Lekki   | Lekki [5]         | 10 (33.3)                              | 1 (3.3) | 9 (30.0) | 9 (30.0) | 9 (30.0) |
| Kosofe        | Madian Community [6] | 1 (3.3)                              | 0    | 1 (3.3)  | 1 (3.3)  | 1 (3.3)  |
|               | Owode/Ajejunule  [7] | 3 (10.0)                              | 0    | 3 (10.0) | 3 (10.0) | 3 (10.0) |
|               | Owode/Elede [8]   | 1 (3.3)                                | 0    | 1 (3.3)  | 1 (3.3)  | 1 (3.3)  |
| Lagos Island  | Sura [11]         | 1 (3.3)                                | 0    | 1 (3.3)  | 1 (3.3)  | 1 (3.3)  |
| Apapa         | Ijora [12]        | 1 (3.3)                                | 0    | 1 (3.3)  | 1 (3.3)  | 1 (3.3)  |
|               | Akere [14]        | 1 (3.3)                                | 0    | 1 (3.3)  | 1 (3.3)  | 1 (3.3)  |
| Armowo Odofin | Monkey Village [17]| 0                                    | 1 (3.3) | 1 (3.3)  | 1 (3.3)  | 1 (3.3)  |
|               | Ijegun [18]       | 0                                      | 3 (10.0) | 3 (10.0) | 3 (10.0) | 3 (10.0) |
| Total         |                   | 30 (100)                               | 1 (3.3) | 29 (96.7) | 29 (96.7) | 29 (96.7) |

LGA Local Government Area.
have important implications for the effectiveness of SP in children less than 5 years of age and in pregnant women [41]. Reports from previous studies within Nigeria and in Africa were: 37.5% and 22.5% of A437G and K540E haplotype mutations respectively in Lagos (2011) [9] and 96.4% of 437G haplotype and no mutation at K540 codon in Calabar (2013/2014) [42],

Table 6 Distribution of dhps mutations at the community locations in Lagos, Nigeria

| LGA/Community | Name of community | No. of samples sequenced for dhps n (%) | dhps mutation n (%) |
|---------------|-------------------|----------------------------------------|---------------------|
| LGA/Community |                   |                                        |                     |
| Ikorodu       | Ipakodo [1]       | 1 (5.0)                                | 0                   |
| Epe           | Agbowa [2]        | 3 (15.0)                               | 2 (10.0)            |
| Ibeju-Lekki   | Lekki [5]         | 9 (45.0)                               | 2 (10.0) 4 (20.0) 9 (45.0) |
| Kosofe        | Owode/Ajegunle [7]| 1 (5.0)                                | 0                   |
| Apapa         | Akere [14]        | 1 (5.0)                                | 0                   |
| Amuwo-Odofin  | Monkey village [17]| 2 (10.0)                              | 0                   |
| Ijegun        | [18]              | 1 (5.0)                                | 0                   |
| Total         |                   | 20 (100)                               | 4 (20.0) 11 (55.0) 20 (100.0) 0 4 (20.0) 9 (45.0) |

Table 7 Prevalence of dhfr and dhps haplotypes in Plasmodium falciparum isolates from Lagos, Nigeria

| Gene Category | Haplotype   | n (%)     |
|---------------|-------------|-----------|
| dhfr | Wild type | CNCSI | 8 (3.3) |
|                | Double mutation | CNRNI | 3 (1.2) |
|                |             | CNRNI | 3 (1.2) |
| dhps | Single mutation | SGKAA | 74 (44.3) |
|                | AAkAA | 4 (2.4) |
|                | Double mutations | AGKAA | 7 (4.2) |
|                | FAKAS | 3 (1.8) |
|                | SGKGA | 2 (1.2) |
|                | AAkGA | 1 (0.6) |
|                | SGKAS | 6 (3.6) |
|                | SGKAA | 2 (1.2) |
|                | VSGKAA | 1 (0.6) |
| dhps | Triple mutations | SGKGS | 9 (5.4) |
|                | VAGKAA | 1 (0.6) |
|                | AGKGA | 1 (0.6) |
|                | AGKAS | 14 (8.4) |
| dhps | Quadruple mutation | AGKGS | 2 (1.2) |
|                | VAGKAS | 3 (1.8) |
|                | VAGKGA | 4 (2.4) |
| dhps | Quintuple mutation | VAGKGS | 33 (19.8) |

Table 8 Prevalence of combined dhfr and dhps haplotypes combinations in Plasmodium falciparum isolates from Lagos, Nigeria

| Gene Category | Haplotype   | n (%)     |
|---------------|-------------|-----------|
| dhfr/dhps | (n = 141) | Triple mutant | CNRNI + SGKAA | 2 (1.4) |
| dhfr | Quadruple Mutant | CNRNI + SGKAA | 60 (42.6) |
| dhfr | Quintuple mutant | CNRNI + AGKAA | 7 (5.0) |
| dhfr | Sextuple mutant | CNRNI + AGKAA | 14 (9.9) |
| dhfr | Octuple mutant | CNRNI + VAGKAA | 31 (22.0) |

Mutations in the haplotype are underlined. Mutated alleles are underlined.
Nigeria. In Mukono District (Uganda), high frequency of mutation in dhps codon 437G (99.1%) and 540E (98.2%) (2010–2012) [43] was reported within the same period in which the samples in our study were collected.

The prevalence of 581G dhps haplotype mutation was (314.4%) and is associated with important modulatory role in resistance [39]. The World Health Organization (WHO) recommends that when the frequency of the 540 dhps haplotype mutation exceeds 95%, IPTp should not be implemented, because it could fail [40]. WHO also recommends that when the frequency of dhps Ala581Gly haplotype is above 10.0%, IPTp with SP may not be able to protect pregnant women from delivering infants with low birth weight [40]. Our study was in the general population and retrospectively, there were no existing data on birth outcomes to correlate this finding in the study areas where the samples were collected between 2010 and 2014. Nevertheless, it underscored the need for regular molecular marker studies in areas where SP is used for malaria interventions. In addition, it is worth noting that the occurrence of the dhps 540E and Ala581Gly haplotype mutations are rare in West Africa, but common in east and southern Africa [39, 44].

The I431V occurred in combination with other dhps haplotype mutations, and the most frequent was VAGKGS haplotype. There were similar reports on this emerging mutation on dhps in Nigeria and Cameroun [10, 21, 22]. The occurrence of I431V mutation in dhps over the years may suggest conferment of selective advantage in the presence of SP drug pressure and displacement of the more sensitive haplotypes. Since SP is used as IPTp, and also readily available in the Nigerian market for treatment of malaria [45], an indication that ongoing SP drug pressure is strong. Another plausible explanation is that dhps haplotype mutation (431 V) has arisen by chance and provided an improvement in the fitness of parasites carrying the 437, 581 and/or 613 mutations, but does not change susceptibility to sulphadoxine [10]. Further studies are needed to assess the effect of this mutation on the phenotype of parasites carrying this haplotype.

Partial resistance to SP [28] in dhfr-dhps haplotypes combinations were described in our study. The prevalence was 42.6% and 22.0% for quadruple haplotype mutations, CIRNI-SGKAA and octuple haplotype (CIRNI + VAGKGS) respectively. Specifically, CIRNI-SGKAA was highly associated with sub-optimal IPTp-SP effectiveness in previous studies [46]. However, K540E haplotype mutation was not found in any of the dhfr-dhps combinations in our study.

In West Africa wild dhps K540 commonly occur with triple dhfr mutations and single 437G dhps mutation [47, 48]. The highest levels and spread of antifolate resistance are found in Southeast Asia and South America [48–50]. In these two regions, a polymorphism at dhfr residue 164 is almost always found, but is rarely seen in sub-Saharan Africa despite extensive use of the drug [48]. Moderate level of resistance conferred by dhfr and dhps polymorphisms is typically found in West Africa with the absence of 1164L polymorphism that is associated with very high-level SP resistance (up to 20 000-fold decrease in susceptibility in comparison with the wild type) [50]. 1164L polymorphism have been variously reported in parts of East Africa [51], some parts of South Africa [52] and Asia [53]. There is dearth of information on why 1164L mutation does not occur in Africa despite extensive drug pressure. It was suggested that this amino acid change carries a high fitness cost to the parasite, such that it is unable to survive the immune response of “malaria-experienced” hosts in West Africa [50]. Nevertheless, though SP is ineffective in treating symptomatic disease in malaria-naïve children in many parts of Africa, it has retained some efficacy in preventing malaria in pregnant women [49].

For consideration that the samples we used in our study were collected nearly 10 years ago, and SP has been restricted to be used in malaria control among general population for several years in Nigeria due to severe drug resistance developed in P. falciparum, recovery of wild type of SP sensitive parasite could probably be expected. Similar situation has ever occurred that chloroquine sensitivity of P. falciparum reappeared after long time stopping of drug use in malaria control [54]. Recent investigation of SP sensitivity of malaria parasite in local area in Nigeria should be proceeded.

Conclusion

This study showed a high prevalence of dhfr and dhps mutant alleles in Plasmodium falciparum isolates in Lagos, Nigeria, indicating that SP resistant parasites were in circulation five to 8 years after the introduction of ACT regimen. There was increased prevalence in dhfr triple haplotype mutations when compared with previous reports in the same environment but aligned with high prevalence in other locations in Nigeria and other countries in Africa. Mutation in dhps, particularly 540E that is scarcely reported was low in this study. Partially dhfr-dhps haplotype mutations were reported while 1164L mutation that is consistently associated with SP resistance was not seen. This study has added to the repertoire of SP haplotype research for analyses of trends and monitoring of threats to continued use of SP. Molecular marker studies on resistant genotypes and haplotypes of SP remains invaluable where the medicine is used in various interventions by national malaria programmes.

Abbreviations
SP: Sulphadoxine–pyrimethamine; ACT: Artemisinin-based combination therapy; Pf dhfr: Plasmodium falciparum dihydrofolate reductase;
dhps: dihydropteroate synthase; IPT: Intermittent preventive treatment; MiP: Malaria in pregnancy; SNPs: Single nucleotide polymorphism

Acknowledgements
We acknowledge the support received from the Lagos State Ministry of Health that gave approval to conduct this study at the facilities and communities from where samples were collected. Sincere thanks to the patients that participated in this study and the management team of the various health facilities namely Ijede General Hospital, Imota Primary Health Centre, Bayeku Primary Health Centre, Agura Primary Health Centre, Ikorodu Lagos; Shomolu General Hospital, Shomolu, and St. Matthew’s Primary Health Centre, Amukoko, Lagos. We thank the Bio Venture for Global Health (BVGH) that fostered the collaboration through the WIPO Re:Search program. The molecular characterization study was sponsored by the Chinese Ministry of Health, China.

Authors’ contributions
HQ, UI and HMS collected the data and wrote the first draft; SO, SBC and CO collected the samples and analyzed the data; and WO, JHC and XNZ designed the experiments; guided the English writing and revised the first draft. All authors read and approved the final manuscript.

Funding
This work was supported by the National Research and Development Plan of China (Grant No. 2018YFE0121600), the Project of Shanghai Science and Technology Commission (Grant No. 18490741100), the National Sharing Service Platform for Parasite Resources (Grant No. TBPX-2019-194-30), the Foundation of National Science and Technology Major Program (Grant no. 2018ZX10734–404 and 2016ZX1000222–004), and the National Natural Science Foundation of China (Grant No. 811101266) and the Open Project of Key Laboratory of Parasite and Vector Biology, Ministry of Health (Grant No. WSBKTKT201405).

Availability of data and materials
Genetic data from this study deposited at the National Center for Biotechnology Information (NCBI). Accession numbers: BankIt2291211: MN985140 - MN985306 (167 sequences) and BankIt2298803: MT140637 - MT140882 (241 Sequences).

Ethics approval and consent to participate
Research Grants and Experimentation Ethics Committee, College of Medicine, University of Lagos, Nigeria and the Ethics Committee of the National Institute of Parasitic Diseases (NIPD), China CDC approved this study protocol. All the research participants / caregivers (in the case of children) gave informed consent/assent. Patients that declined to participate in the protocol. All the research participants / caregivers (in the case of children) gave informed consent/assent. Patients that declined to participate in the protocol.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Chinese Center for Tropical Diseases Research, WHO Collaborating Center for Tropical Diseases, National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Key Laboratory of Parasite and Vector Biology, Ministry of Health, Shanghai 200025, People’s Republic of China. 2National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention–Shenzhen Center for Disease Control and Prevention Joint Laboratory for Imported Tropical Disease Control, Shanghai 200025, People’s Republic of China. 3Center for Infectious Diseases Research, Microbiology Department, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, Nigeria. 4ANDI Center of Excellence for Malaria Diagnosis, Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria. 5Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria. 6Department of Surveying and Geoinformatics, Faculty of Engineering, University of Lagos, Lagos, Nigeria.

Received: 13 December 2019 Accepted: 1 July 2020

References
1. WHO. Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000–2010. 2010.
2. FMoH: Federal ministry of health N, PP. 126. National Malaria Control Programme in Nigeria. Annual Report 2005.
3. Uhlemann AC, Krishna S. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr Top Microbiol Immunol. 2005;295:39–53.
4. Wellemes TE, Plowe CM. Chloroquine-resistant malaria. J Infect Dis. 2001;184: 770–6.
5. Wongrichinan C, Pickard AL, Wemsderfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:299–8.
6. WHO. World Health Malaria Report. World Health Organization. 2014.
7. Desai M, Gutman J, Taylor SM, Wiegand RE, Khalilah C, Kayentao K, et al. Impact of sulfadoxine-pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low birth weight. Clin Infect Dis. 2016;62(3):323–32.
8. Agomo CO, Obiko WA, Sutherland C, Hallett R, Oguku M. Assessment of markers of antimalarial drug resistance in Plasmodium falciparum isolates from pregnant women in Lagos, Nigeria. PLoS One. 2016;11(11):e0146908.
9. Iwalokun BA, Iwalokun SO, Adebodun V, Balogun M. Carriage of mutant dihydrofolate reductase and dihydropteroate synthase genes among Plasmodium falciparum isolates recovered from pregnant women with asymptomatic infection in Lagos, Nigeria. Med Princ Pract. 2015;24(5):436–43.
10. Oguke MC, Falade CO, Shu E, Enato IG, Watila I, Baba ES, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V. Int J Parasitol Drugs Drug Resist. 2016(6):225–9.
11. Wang P, Lee CS, Bayoumi R, Dzino A, Dourou M, Swedberg G, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol. 1997;89(2):161–77.
12. Deckmann A, Jung A. Mechanisms of sulfonamide resistance in Plasmodium falciparum. Mol Biochem Parasitol. 1986;19(2):143–7.
13. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1997;94(25):13944–9.
14. Chulay JD, Watkins WM, Sixsmith DG. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1984;33(3):325–30.
15. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A. 1988;85(23):9109–13.
16. Contirees CE, Cortes JE, Caraballo A, Plowe CV. Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. Am J Trop Med Hyg. 2002;67(4):400–5.
17. Khalil I, Rann AM, Alfaraghs M, Gabar HA, Satti GM, Bygbjerg IC. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am J Trop Med Hyg. 2003;68(5):586–91.
18. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 1998;17(14):3807–15.
19. Berglez J, Ilades P, Siravarporn W, Coloe P, Macreadie I. Analysis in vitro of Plasmodium falciparum dihydropteroate synthase (DHP5) alleles implicated in resistance to sulfadoxine. Int J Parasitol. 2004;34(1):195–100.
20. Pearce RJ, Pota H, Evseeva MS, Bä EH, Mombo-Ngoma G, Malisa AL, Ord R, et al. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med. 2009;6(4):e1000055.
21. Sutherland CJ, Filer H, Pearce RJ, Reza F, Nicholas M, Haustein T, NJingye Tekumafro NE, et al. Novel pfmdr1 haplotypes among imported cases of
Plasmodium falciparum malaria in the United Kingdom. Antimicrob Agents Chemother. 2009;53(8):3405–10.
22. Chauvin P, Menard S, Iriart X, Nsango SE, Tchioffo MT, Abate L, et al. Prevalence of Plasmodium falciparum parasitemia resistant to sulfadoxine/pyrimethamine in pregnant women in Yaoundé, Cameroon: emergence of highly resistant pf dhfr/dhps alleles. J Antimicrob Chemother. 2015;70(9): 2566–71.
23. Plowe CV. The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg. 2009;103(Suppl 1):S11–4.
24. Kun JF, Lehman LG, Lell B, Schmidt-Ott R, Kremsner PG. Low-dose treatment with sulfadoxine-pyrimethamine combinations select for drug-resistant Plasmodium falciparum strains. Antimicrob Agents Chemother. 1999;43(9): 2205–8.
25. Kublin JG, Djizjalamala FK, Kamwenddo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RAG, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185(3):380–8.
26. Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, et al. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005;93(3):183–93.
27. Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, Do Rosário V, Covo P, et al. Malaria parasites can develop stable resistance to artesinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tcp1, mdr1, and cg10. Antimicrob Agents Chemother. 2006;50(2):480–9.
28. Naido I, Roper C. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria. Trends Parasitol. 2013;29(10):505–15.
29. Odusanya OO, Akinyinka MR, Olusegbe OA, Odugbemi BA, Bakare OQ, et al. Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine/pyrimethamine in pregnant women in Yaoundé, Cameroon: emergence of highly resistant pf dhfr/dhps alleles. J Antimicrob Chemother. 2009;53(8):3405–10.
30. National Population Commision (NPC) (Nigeria) NMCPNNaII. Nigeria Malaria Control Report 2004.
31. WHO. Basic Laboratory methods in Medical Parasitology. Geneva: World Health Organization; 1991.
32. Alam MT, de Souza DK, Vinayak S, Griffing SM, Poe AC, Duah NO, et al. Selection sweeps and genetic lineages of Plasmodium falciparum drug-resistant alleles in Ghana. J Infect Dis. 2011;203:220–7.
33. Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Shah NK, et al. Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine/pyrimethamine in pregnant women from Lubango, Angola. Malar J. 2016;15(1):309.
34. Jiang T, Chen J, Fu H, Wu K, Yao Y, Eyi JUM, et al. High prevalence of Pfdhfr and Pfdhps pyrimethamine resistance among asymptomatic pregnant women in Southeast Nigeria. Parasitol Res. 2018;117(3):801–7.
35. Mbonye AK, Bruni) J, Yanow SK, Shkoples S, Malamba S, Alifrangis M, et al. Prevalence of Plasmodium falciparum sulfadoxine-pyrimethamine resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda. Antimicrob Agents Chemother. 2015;59(9):5475–82.
36. van Eijk AM, Lansen DA, Kayentao K, Koshy G, Slaughter DEC, Roper C, et al. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(5):546–56.
37. WHO. WHO Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy. Geneva: World Health Organization; 2013.
38. Chico RM, Cano J, Artzi C, Collier TJ, Chandramohan D, Roper C, et al. Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis. Tropical Med Int Health. 2015;20(12):1621–33.
39. Esu E, Taloji C, Gai P, Berens-Riha N, Pritch M, Loechener T, et al. Prevalence of the Pfdhfr and Pfdhps mutations among asymptomatic pregnant women in Southeast Nigeria. Parasitol Res. 2018;117(3):801–7.
40. WHO. WHO Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy. Geneva: World Health Organization; 2013.